SHP2-IN-13
Based on 1 Customer Validation
SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 2951854-02-5
- Formula: C16H21N7O
- Molecular Weight:327.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Orally Active Compound Library
HY-L061
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Biological Activity
SHP2-IN-13 (compound 129) potently inhibits the pERK signaling in a dose-dependent manner with IC50 values of 0.59 μM and 0.63 ± 0.32 μM in NSCLC cells and NCI–H1975-OR cells, respectively.[1]. SHP2-IN-13 (0-30 μM; 24 hours) inhibited pERK levels and receptor tyrosine kinase (RTK)-driven cancer cell proliferation in NCI–H1975 cells, . And it also inhibits phosphorylated ERK (pERK) levels in receptor tyrosine kinase (RTK)-resistant NSCLC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NSCLC cells or NCI–H1975-OR cells
-
Concentration:0 μM, 0.01 μM, 0.04 μM, 0.1 μM, 0.4 μM, 1.1 μM, 3.3 μM, 10 μM, 30 μM
-
Incubation Time:24 hours
-
Result:Inhibited p-ERK expression in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Murine NSG xenograft model inoculated with FLT3-ITD mutated MV-4-11-luciferase (MV-4-11-Luc) AML cells[1]
-
Dosage:20 mg/kg
-
Administration:Oral gavage; 20 mg/kg; daily
-
Result:Exhibited an anti-tumour efficacy in AML model.
Chemical Information
-
CAS No. 2951854-02-5
-
Appearance Solid
-
Molecular Weight 327.38
-
Formula C16H21N7O
-
Color Off-white to light yellow
-
SMILES
CC1(CCN(CC1)C2=NC=C(C(N)=N2)C(NC3=CN=CC=C3)=O)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (152.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0546 mL | 15.2728 mL | 30.5455 mL | 76.3639 mL |
| 5 mM | 0.6109 mL | 3.0546 mL | 6.1091 mL | 15.2728 mL | |
| 10 mM | 0.3055 mL | 1.5273 mL | 3.0546 mL | 7.6364 mL | |
| 15 mM | 0.2036 mL | 1.0182 mL | 2.0364 mL | 5.0909 mL | |
| 20 mM | 0.1527 mL | 0.7636 mL | 1.5273 mL | 3.8182 mL | |
| 25 mM | 0.1222 mL | 0.6109 mL | 1.2218 mL | 3.0546 mL | |
| 30 mM | 0.1018 mL | 0.5091 mL | 1.0182 mL | 2.5455 mL | |
| 40 mM | 0.0764 mL | 0.3818 mL | 0.7636 mL | 1.9091 mL | |
| 50 mM | 0.0611 mL | 0.3055 mL | 0.6109 mL | 1.5273 mL | |
| 60 mM | 0.0509 mL | 0.2545 mL | 0.5091 mL | 1.2727 mL | |
| 80 mM | 0.0382 mL | 0.1909 mL | 0.3818 mL | 0.9545 mL | |
| 100 mM | 0.0305 mL | 0.1527 mL | 0.3055 mL | 0.7636 mL |
Powered by Bioz